المؤلفون: Ardighieri, L, Missale, F, Bugatti, M, Gatta, LB, Pezzali, I, Monti, M, Gottardi, S, Zanotti, L, Bignotti, E, Ravaggi, A, Tognon, G, Odicino, F, Calza, S, Missolo-Koussou, Y, Ries, CH, Helft, J, Vermi, W

المصدر: Frontiers in immunology. 12:690201

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:147007251

المؤلفون: Foekens, J A, Ries, Ch, Look, M P, Gippner-Steppert, C, Klijn, J G M, Jochum, M

المصدر: British Journal of Cancer; 4/7/2003, Vol. 88 Issue 7, p1084-1090, 7p

مصطلحات موضوعية: NEUTROPHILS, BREAST cancer, TAMOXIFEN, PROTEIN analysis, RESEARCH, MULTIVARIATE analysis, RESEARCH methodology, PROTEOLYTIC enzymes, CELL receptors, EVALUATION research, COMPARATIVE studies, BREAST tumors

المؤلفون: Bögli Nicole C, Ries Christoph, Bauer Irina, Adams Thorsten, Greller Gerhard, Eibl Regine, Eibl Dieter

المصدر: BMC Proceedings, Vol 5, Iss Suppl 8, p P124 (2011)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1753-6561

URL الوصول: https://doaj.org/article/4eedb9ddd1234fefa014141b3c98656c

المؤلفون: Domingos-Pereira S; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Sathiyanadan K; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Polak L; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Haefliger JA; Department of Medicine, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Schmittnaegel M; Roche Innovation Center Munich, Pharma Research and Early Development, 82377 Penzberg, Germany., Ries CH; Roche Innovation Center Munich, Pharma Research and Early Development, 82377 Penzberg, Germany., Jichlinski P; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Roth B; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Derré L; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland., Nardelli-Haefliger D; Department of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Dec 21; Vol. 24 (1). Date of Electronic Publication: 2022 Dec 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: B7-H1 Antigen* , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/metabolism, Animals ; Mice ; Urinary Bladder/pathology ; Myeloid Cells/metabolism ; Chemokines/metabolism ; Cell Line, Tumor ; Tumor Microenvironment

المؤلفون: Murgaski A; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Kiss M; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Van Damme H; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Kancheva D; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Vanmeerbeek I; Laboratory of Cell Stress & Immunity (CSI), Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium., Keirsse J; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Hadadi E; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Brughmans J; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Arnouk SM; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Hamouda AEI; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Debraekeleer A; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Bosteels V; Laboratory for ER stress and Inflammation, VIB Center for Inflammation Research, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium., Elkrim Y; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Boon L; JJP Biologics, Warsaw, Poland., Hoves S; Roche Pharmaceutical Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Vandamme N; Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium.; Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium., Deschoemaeker S; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium., Janssens S; Laboratory for ER stress and Inflammation, VIB Center for Inflammation Research, Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium., Garg AD; Laboratory of Cell Stress & Immunity (CSI), Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium., Vande Velde G; Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven, Belgium., Schmittnaegel M; Roche Pharmaceutical Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Ries CH; Roche Pharmaceutical Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Laoui D; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

المصدر: Cancer research [Cancer Res] 2022 Oct 17; Vol. 82 (20), pp. 3785-3801.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: CD40 Antigens*/agonists , Dendritic Cells*/metabolism , Macrophages*/metabolism , Neoplasms*/metabolism, Animals ; CD8-Positive T-Lymphocytes ; Humans ; Mice ; Mice, Inbred C57BL

المؤلفون: Kos K; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Salvagno C; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Obstetrics and Gynecology, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States., Wellenstein MD; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht, Utrecht, The Netherlands., Aslam MA; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer DA; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Hau CS; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Vrijland K; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Kaldenbach D; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Raeven EAM; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Schmittnaegel M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Ries CH; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., de Visser KE; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.

المصدر: Oncoimmunology [Oncoimmunology] 2022 Apr 15; Vol. 11 (1), pp. 2063225. Date of Electronic Publication: 2022 Apr 15 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms* , T-Lymphocytes, Regulatory*, Female ; Humans ; Immune Tolerance ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment ; Tumor-Associated Macrophages

المؤلفون: Martinez-Usatorre A; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland., Kadioglu E; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland., Boivin G; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland., Cianciaruso C; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland., Guichard A; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland., Torchia B; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland., Zangger N; Bioinformatics Core Facility (BCF), SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland., Nassiri S; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Agora Cancer Research Center, 1011 Lausanne, Switzerland.; Bioinformatics Core Facility (BCF), SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland., Keklikoglou I; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland., Schmittnaegel M; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early Development, 82377 Penzberg, Germany., Ries CH; Roche Innovation Center Munich, Oncology Discovery, Pharma Research and Early Development, 82377 Penzberg, Germany., Meylan E; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland., De Palma M; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland. michele.depalma@epfl.ch.; Agora Cancer Research Center, 1011 Lausanne, Switzerland.

المصدر: Science translational medicine [Sci Transl Med] 2021 Aug 11; Vol. 13 (606).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Animals ; B7-H1 Antigen ; CD8-Positive T-Lymphocytes ; Humans ; Mice ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment ; Vascular Endothelial Growth Factor A

المؤلفون: Bissinger S; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany. bissins@gmail.com riescarola@gmx.de., Hage C; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Wagner V; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Maser IP; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Brand V; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Schmittnaegel M; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Jegg AM; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Cannarile M; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Watson C, Klaman I; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Rieder N; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., González Loyola A; Department of Oncology, University of Lausanne (UNIL) and Ludwig Institute for Cancer Research Lausanne (LICR), 1066 Epalinges, Switzerland., Petrova TV; Department of Oncology, University of Lausanne (UNIL) and Ludwig Institute for Cancer Research Lausanne (LICR), 1066 Epalinges, Switzerland., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France., Gomez-Roca C; Institut Claudius Regaud/Institut Universitaire du Cancer, Toulouse Oncopole, 31300 Toulouse, France., Sibaud V; Institut Claudius Regaud/Institut Universitaire du Cancer, Toulouse Oncopole, 31300 Toulouse, France., De Palma M; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland., Hoves S; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany., Ries CH; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, 82377 Penzberg, Germany. bissins@gmail.com riescarola@gmx.de.

المصدر: Science translational medicine [Sci Transl Med] 2021 Jun 16; Vol. 13 (598).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: Edema* , Macrophages* , Neoplasms* , Peptide Hydrolases* , Proteoglycans*, Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Mice ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors

المؤلفون: Przystal JM; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany., Becker H; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany., Canjuga D; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany., Tsiami F; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany., Anderle N; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany., Keller AL; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany., Pohl A; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany., Ries CH; Roche Innovation Center Munich, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Schmittnaegel M; Roche Innovation Center Munich, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Korinetska N; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany., Koch M; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany., Schittenhelm J; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.; Institute for Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany., Tatagiba M; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; Department of Neurosurgery, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany., Schmees C; NMI, Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany., Beck SC; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany., Tabatabai G; Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.; German Translational Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tübingen, 72076 Tübingen, Germany.

المصدر: Cancers [Cancers (Basel)] 2021 May 15; Vol. 13 (10). Date of Electronic Publication: 2021 May 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Cassier PA; Centre Léon Bérard, Département D'Oncologie Médicale, Lyon, France., Italiano A; Institut Bergonie, Oncologie, Bordeaux, France., Gomez-Roca C; Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France., Toulmonde M; Institut Bergonie, Oncologie, Bordeaux, France., D'Angelo SP; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA., Weber K; University of Pennsylvania, Philadelphia, USA., Loirat D; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Jacob W; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany. Electronic address: wolfgang.jacob@roche.com., Jegg AM; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Michielin F; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland., Christen R; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland., Watson C; A4P Ltd, Sandwich, UK., Cannarile M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Klaman I; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Abiraj K; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland., Ries CH; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Weisser M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Rüttinger D; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Blay JY; Centre Léon Bérard, Département D'Oncologie Médicale, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Unicancer, Paris, France., Delord JP; Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Dec; Vol. 141, pp. 162-170. Date of Electronic Publication: 2020 Nov 05.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life*, Antibodies, Monoclonal, Humanized/*therapeutic use , Antineoplastic Agents, Immunological/*therapeutic use , Synovitis, Pigmented Villonodular/*drug therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Young Adult